 WATERTOWN, Mass., July 20, 2021 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to receive a nine month extension on DEXYCUs pass-through payment status, which otherwise would expire on March 31, 2022. 